

## Murlentamab

Cat. No.:	HY-P99746
CAS No.:	2058047-65-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Murlentamab (3C23K; GM102) is a humanized anti-AMHR II antibody. AMHR II is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming <sup>[1]</sup> .
IC <sub>50</sub> & Target	AMHR II <sup>[1]</sup>
In Vivo	Murlentamab (20 mg/kg; i.v.; twice weekly for 4 weeks) inhibits tumor growth in mouse hepatocarcinoma PDX model in vivo <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHR II) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogramming and T Cell Activation. *Cancers (Basel)*. 2021 Apr 13;13(8):1845.
- [2]. Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHR II) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. *Biology (Basel)*. 2021 Apr 7;10(4):305.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA